Search - tctmd.com

Displaying 1 - 20 of 32

Sort: Relevancy | Date

Presentation TCT 2016

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

Presenter: Martin W. Bergmann, Samir R. Kapadia, Harvey D. White

November 01, 2016

Presentation TCT 2016

What Is Known (and What Is Not) About Discontinuing Aspirin or Clopidogrel in Patients on Chronic Oral Anticoagulants Plus DAPT

Presenter: David P. Faxon, C. Michael Gibson, Freek W.A. Verheugt

November 01, 2016

Presentation TCT 2016

The Big Picture: Incremental Bleeding Risks in Patients Requiring Chronic Oral Anticoagulants Plus DAPT

Presenter: David P. Faxon, C. Michael Gibson, Christopher B. Granger

November 01, 2016

Presentation TCT 2016

Chronic Oral Anticoagulants: Limitations, Use Recommendations, and Investigational Agents

Presenter: Paul A. Gurbel, Christopher B. Granger

October 30, 2016

Presentation Fellows 2016

How to Navigate the New Oral Anticoagulants and Deal With Triple Therapy

Presenter: Roxana Mehran

April 15, 2016

Presentation

Time to Cost-Effectiveness After Stroke Reduction Strategies in A-fib: Warfarin vs Novel Oral Anticoagulants (NOACs) vs Left Atrial Appendage (LAA) Closure

Presenter: Vivek Y. Reddy

December 13, 2015

Presentation TCT 2015

Is There a Role for Oral Anticoagulants After PCI?

Presenter: Eric R. Bates, Neal S. Kleiman, C. Michael Gibson

October 15, 2015

Presentation TCT 2015

How Good Is LAA Closure Compared to Oral Anticoagulants? Results of Studies

Presenter: Russell A. Brandwein, Elizabeth M Perpetua

October 11, 2015

Presentation Fellows 2015

How to Navigate the New Oral Anticoagulants and Deal With Triple Therapy

Presenter: Manish A. Parikh, Roxana Mehran

May 15, 2015

Presentation

Risk of GI bleeding With Oral Anticoagulants: Population-Based Retrospective Cohort Study

Presenter: Hsien-Yen Chang

May 01, 2015

Presentation

Of 7,372 patients from the ORBIT-AF registry treated with oral anticoagulants, 2,200 had at least 1 interruption and bridging was used in 24%_

Presenter: Benjamin A. Steinberg

December 22, 2014

Presentation TCT 2014

Cost-effectiveness Analysis Of Left Atrial Appendage Occlusion Device Compared With 7 Oral Anticoagulants For Stroke Prevention In Atrial Fibrillation

Presenter: Vivian Lee

September 16, 2014

Presentation TCT 2014

TCT 170: Cost-effectiveness Analysis of a Left Atrial Appendage Occlusion Device Compared with 7 Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation

Presenter: Saibal Kar, Bushra S Rana, Jai-Wun Park, Vivian Lee

September 15, 2014

Presentation TCT 2014

Role of New Oral Anticoagulants and New ADP Antagonists in ACS Patients

Presenter: Roxana Mehran, Mohamed Sobhy

September 13, 2014

Presentation Fellows 2014

Navigating the New Oral Anticoagulants and Triple Therapy

Presenter: George D. Dangas

April 13, 2014

Presentation Fellows 2014

Navigating the New Oral Anticoagulants and How to Deal with Triple Therapy

Presenter: George Dangas

April 12, 2014

Presentation

Comparison of the Efficacy and Safety of New Oral Anticoagulants with Warfarin in A-fib Patients

Presenter: C.T. Ruff

December 15, 2013

Presentation

New Oral Anticoagulants and the Risk of Intracranial Hemorrhage

Presenter: Saurav Chatterjee

December 15, 2013

Presentation TCT 2013

Management of a Patient on Novel Oral Anticoagulants Needing Urgent Cath

Presenter: Michael Ezekowitz

October 31, 2013

Presentation TCT 2013

Reversal Strategies Warfarin and the New Oral Anticoagulants: How Necessary, How Fast, How Safe, How Effective?

Presenter: Kurt Huber

October 31, 2013

Advertisement

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

What Is Known (and What Is Not) About Discontinuing Aspirin or Clopidogrel in Patients on Chronic Oral Anticoagulants Plus DAPT

The Big Picture: Incremental Bleeding Risks in Patients Requiring Chronic Oral Anticoagulants Plus DAPT

Chronic Oral Anticoagulants: Limitations, Use Recommendations, and Investigational Agents

How to Navigate the New Oral Anticoagulants and Deal With Triple Therapy

Time to Cost-Effectiveness After Stroke Reduction Strategies in A-fib: Warfarin vs Novel Oral Anticoagulants (NOACs) vs Left Atrial Appendage (LAA) Closure

Is There a Role for Oral Anticoagulants After PCI?

How Good Is LAA Closure Compared to Oral Anticoagulants? Results of Studies

How to Navigate the New Oral Anticoagulants and Deal With Triple Therapy

Risk of GI bleeding With Oral Anticoagulants: Population-Based Retrospective Cohort Study

Of 7,372 patients from the ORBIT-AF registry treated with oral anticoagulants, 2,200 had at least 1 interruption and bridging was used in 24%_

Cost-effectiveness Analysis Of Left Atrial Appendage Occlusion Device Compared With 7 Oral Anticoagulants For Stroke Prevention In Atrial Fibrillation

TCT 170: Cost-effectiveness Analysis of a Left Atrial Appendage Occlusion Device Compared with 7 Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation

Role of New Oral Anticoagulants and New ADP Antagonists in ACS Patients

Navigating the New Oral Anticoagulants and Triple Therapy

Navigating the New Oral Anticoagulants and How to Deal with Triple Therapy

Comparison of the Efficacy and Safety of New Oral Anticoagulants with Warfarin in A-fib Patients

New Oral Anticoagulants and the Risk of Intracranial Hemorrhage

Management of a Patient on Novel Oral Anticoagulants Needing Urgent Cath

Reversal Strategies Warfarin and the New Oral Anticoagulants: How Necessary, How Fast, How Safe, How Effective?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content